Mar 17–20, 2024 | Fairmont Chateau Whistler, Whistler, BC, Canada
Scientific Organizers:
James P. Allison, Andrea Schietinger, Antoni Ribas, and Padmanee Sharma

-
Scientific Organizers: James P. Allison, Andrea Schietinger, Antoni Ribas, and Padmanee Sharma
James P. Allison
Andrea Schietinger
Antoni Ribas
Padmanee Sharma
***Meeting program subject to change.
Available Formats: = In Person = On DemandImmune Checkpoint Blockade in Cancer Therapy: New Insights into Therapeutic Mechanisms of anti-CTLA4 and anti-PD-1
Single Agent PD-1 Blockade as Curative-Intent Treatment in Mismatch Repair Deficient Locally Advanced Rectal Cancer
Role of IFN-gamma in Response and Resistance to Cancer Immunotherapies
Neoadjuvant and Tissue-based Trials for Evaluating Mechanisms of Response and Resistance
Neoadjuvant Therapy: Where We Have Come from and Where to Next
Molecular and Spatial Correlates of Response to PD-1 Blockade in Human Tumors
A Stem-Like CD4 T Cell Controls Immunity to Cancer
Galectins: Emerging Glyco-Checkpoints in the Tumor Microenvironment
Short Talk: Short Talk: The Signal Strength of Signal 2 and 3 During T Cell Priming Affect the Functional Fate of an Anti-tumor T Cell Response
Short Talk: Short Talk: Spatial Relationship of Tertiary Lymphoid Structures and Neutrophils in Bladder Cancer and Prognostic Potential for PD-L1 Immunotherapy
Short Talk: Short Talk: PD-1/cDC1 Axis in the Tumor Draining Lymph Node Regulates Stem-like CD8+ T Cell Differentiation
Tuesday, March 19, 2024
Anti-TIGIT Antibody Tiragolumab Leverages Myeloid Cells and Regulatory T Cells to Improve PD-L1 Checkpoint Blockade
Fc-silent anti-TIGIT Antibodies Offer Best-in-class Potential by Potentiating Robust CD8+ T Cell Mediated Anti-tumor Immunity Without Peripheral Regulatory T Cell Depletion
PVRIG is Uniquely Expressed in Tumor Dendritic Cell-rich Niches on Stem-like Memory T Cells and its Blockade May Induce Immune Infiltration and Activation in Non-inflamed Tumors
VISTA-101 – An Ongoing Phase 1/2 Clinical Trial of KVA12123 Targeting VISTA, Alone and in Combination with Pembrolizumab in Advanced Solid Tumors
VISTA Checkpoint Targeting by SNS-101, a pH-selective Antibody with Enhanced Safety and Pharmacokinetic Profiles, Alters the Tumor Microenvironment and Overcomes Immune Checkpoint Inhibitor Resistance
Talk Title to be Announced
PD-1 + IL-2 to Drive Differentiation of Effector T Cells in Tumor
Uncovering Hidden Drivers of Immune Evasion: Stemness and Cell Cycle
Short Talk: Short Talk: Epigenetically Poised IL-7R+ CD8+ T Cells are Critical for Anti-melanoma Memory
Short Talk: Short Talk: Unleashing Natural IL-18 Activity Using an Anti-IL-18BP Blocker Antibody Induces Potent Immune Stimulation and Anti-tumor Effects
Short Talk: Short Talk: Unravelling Tumor-intrinsic Resistance Mechanisms to T-cell Mediated Cytotoxicity in Pancreatic Cancer
Short Talk: Short Talk: CD40 Agonist Systemically Drives the Expansion of Tumor-Specific CD8 T Cells into a PD1+ KLRG1+ Effector State
Group Leader of VHIO´s Tumor Immunology and Immunotherapy Group
Associate Attending Physician
Chief Scientific Officer
Staff Scientist and Head of the Molecular Immunology Group of the Center for Immuno-Oncology, NCI
Gaining Insight into Tumor Immunity by Combining New Highly Multiplex 2D and 3D Imaging with Analytical Tools
Immune Pathology from the Subcellular Scale on Up
Spatial CRISPR
Short Talk: Short Talk: Exploring Resistance Mechanisms to Immune Checkpoint Inhibitor-based Therapies through Single-cell Analysis of Renal Cell Carcinoma
Short Talk: Short Talk: Mature Endothelial Vessels Facilitate Tumor-infiltration by Checkpoint Positive T Cells Following Ipilimumab in Anti-PD-1-resistant Tumors
Wednesday, March 20, 2024
Catalytically Inactive cGAS Potentiates Antitumor Immunity
The Exonuclease TREX1 Constitutes an Innate Immune Checkpoint Limiting cGAS/STING-Mediated Anti-tumor Immunity
Leukemia Inhibitory Factor Fosters Immune Evasion in KRAS-driven Pancreatic Ductal Adenocarcinoma
Modified IL-18 Combined with Anti-PD1 Elicits a CD4+ T Cell-mediated Antitumor Response in MHC Class I-deficient Models of Non-small Cell Lung Cancer
C1q Impairs the Response to Immunotherapies in Glioblastoma
Glioma-neuronal Circuit Remodeling Induces Regional Immunosuppression
The Dendritic Cell Receptor DNGR-1 Couples Dead Cell Sensing to Cancer Immunoediting
Stochasticity in Cancer Immunotherapy Maps with the Rarity of Critical Spark T Cells
Engineering Next-Generation CAR-T Cells for Cancer Immunotherapy
Chimeric Antigen Receptor T-Cells and Carbohydrate-Based Cancer Targets
Synthetic Immunology and Genome Editing Tools to Advance T Cell Therapies
Short Talk: Short Talk: Delayed Tumor Regression Following TCR-T, Anti-PD-L1 and IFNγ Combination Therapy in a Patient with Checkpoint Blockade-refractory HLA-downregulated Merkel Cell Carcinoma
Short Talk: Short Talk: Ikaros Family Transcription Factors Cooperatively Enforce T Cell Exhaustion and Restrain CAR T Cell Efficacy
Short Talk: Short Talk: Mapping CAR and TCR T Cell Exhaustion through Combinatorial CRISPR Screens
Short Talk: Short Talk: Uncovering a Novel Role for IL-4 in the Development of CART Cell Exhaustion
Neoantigen Targeting with Tumor Infiltrating Lymphocytes
Short Talk: Short Talk: Exploring the Potential use of Alternate Neoantigens for the Generation of Therapeutic Cancer Vaccines to Improve Efficacy of Immune Checkpoint Blockade
Short Talk: Short Talk: Overlapping and Distinct Mechanisms of Effective Neoantigen Cancer Vaccines and Immune Checkpoint Therapy
Histone Lactylation(s) Orchestrate Epigenetic and Transcriptional Networks Driving CD8 T Function
Subscribe for Updates